Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1156
- Registration Number
- NCT06671912
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- Drug: AbemaciclibProcedure: BiopsyProcedure: Biospecimen CollectionDrug: FulvestrantProcedure: Bone ScanDrug: CarboplatinDrug: OlaparibProcedure: EchocardiographyDrug: GemcitabineDrug: PemetrexedDrug: ExemestaneDrug: LetrozoleDrug: GefitinibProcedure: Multigated Acquisition ScanOther: Survey AdministrationDrug: TamoxifenDrug: TemozolomideDrug: PaclitaxelDrug: OsimertinibDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 4220
- Registration Number
- NCT06492616
- Locations
- 🇺🇸
Cancer Centers of Kansas, Wichita, Kansas, United States
🇺🇸Miami Valley Hospital South, Centerville, Ohio, United States
🇺🇸Virginia Cancer Institute, Mechanicsville, Virginia, United States
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06428396
- Locations
- 🇨🇱
Centro de Investigación del Maule ( Site 4106), Talca, Maule, Chile
🇺🇸Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia, United States
🇺🇸CHRISTUS Highland ( Site 0005), Shreveport, Louisiana, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Region Örebro County
- Target Recruit Count
- 3832
- Registration Number
- NCT06223698
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪University Hospital of Umeå, Umeå, Sweden
🇸🇪Akademiska University Hospital Uppsala, Uppsala, Sweden
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Conditions
- Locally Advanced Unresectable HER2-Negative Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Locally Advanced Unresectable Hormone Receptor-Positive Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AnastrozoleProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Diagnostic ImagingDrug: ExemestaneOther: Fludeoxyglucose F-18Drug: Fluorine F 18 Fluoro Furanyl NorprogesteroneDrug: FulvestrantBiological: Gonadotropin-releasing Hormone AnalogDrug: LetrozoleProcedure: Positron Emission TomographyDrug: TamoxifenDrug: Therapeutic Estradiol
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT06179303
- Locations
- 🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT06169124
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Helen F Graham Cancer Center, Newark, Delaware, United States
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT06105632
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇨🇦CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, Quebec City, Quebec, Canada
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 400
- Registration Number
- NCT06075953
- Locations
- 🇺🇸
Berkeley Outpatient Center, Berkeley, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.